U.S. Hospitality Stock News

If you are wondering whether Par Pacific Holdings' share price still reflects good value or if too much optimism is already priced in, this article walks through the key numbers that matter for you. The stock recently closed at US$39.25, with returns of 11.9% over the past 7 days, 9.6% over the past 30 days, and 121.1% over the last year, which has put valuation firmly on many investors' radar. Recent news coverage has focused on Par Pacific Holdings as an energy refiner and marketer that...

Why Endava is back on investors’ radar Endava (DAVA) is drawing fresh attention after recent commentary highlighted slower revenue growth, cautious enterprise customer spending, conservative guidance, and a more measured view of its longer term growth prospects. See our latest analysis for Endava. That cautious tone has been reflected in Endava’s recent trading, with a 1 day share price return of 10.24% decline and a 90 day share price return of 36.9% decline. The 1 year total shareholder...

Renewed attention on Carnival Corporation & (CCL) follows its record 2025 revenue, higher profits, and management’s decision to resume dividends while continuing to reduce pandemic era debt obligations. See our latest analysis for Carnival Corporation &. The share price has eased 1.6% over the last day, but that comes after an 11.3% 7-day gain and an 18.7% 90-day share price return. The 3-year total shareholder return of 162% and 5-year total shareholder return of 52% point to momentum that...

If you are wondering whether Thermo Fisher Scientific's current share price reflects its long term potential, you are not alone. This article will help you frame what the recent moves might mean for value focused investors. The stock last closed at US$570.09, with returns of an 8.6% decline over the past 7 days, a 3.8% decline over the past month, and a 3.8% decline year to date, while the 1 year return is a 1.5% decline and the 5 year return stands at 18.1%. Recent share price moves have...

nVent Electric plc recently announced plans to host its 2026 Investor Day on February 24, featuring senior leadership presentations on updated medium-term financial objectives and the next phase of its growth strategy, with live and on-demand webcasts available via its Investor Relations website. This event underscores management’s effort to provide greater transparency around the company’s growth priorities, offering investors a closer look at how its electrical connection and protection...

McDonald's launched limited-edition McNugget Caviar kits in partnership with Paramount Caviar, pairing Chicken McNuggets with premium caviar and specialty sauces. The company also announced leadership changes, including Luis Quintiliano becoming U.S. National Field president and several senior finance rotations. These updates arrive as McDonald's, ticker NYSE:MCD, continues to draw attention from both consumers and investors. For investors, the timing of these moves comes with McDonald's...

In late January 2026, HCA Healthcare reported Q4 and full-year 2025 results showing higher sales, earnings, and diluted EPS, while also issuing 2026 guidance, raising its quarterly dividend to US$0.78 per share, and authorizing a new US$10.00 billion share repurchase program. Management underscored that these financial results were supported by nineteenth consecutive quarter volume growth and expanding AI-driven efficiency initiatives across HCA’s hospital network. Next, we’ll examine how...

Mercury Systems recently reported fiscal second-quarter 2026 results, with sales rising to US$232.87 million and net loss narrowing to US$15.1 million compared with the prior year period. Beyond the headline beat on revenue and adjusted earnings, the company’s record backlog approaching US$1.50 billion underscores strong order inflows and program momentum across areas like space and advanced air mobility. We’ll now explore how these better-than-expected results and record backlog shape...

Why Blue Bird Stock Is On Investors’ Radar Blue Bird (BLBD) has drawn fresh attention after a period of strong share performance, with the stock up 12.1% over the past month and 2.1% over the past 3 months. See our latest analysis for Blue Bird. The recent 12.2% year to date share price return, alongside a 45% total shareholder return over the past year and very large 3 year gains, points to momentum that reflects changing expectations around Blue Bird’s growth prospects and risks at a share...

If you are wondering whether Madrigal Pharmaceuticals' current share price reflects its true worth, this article will walk through what the numbers are saying about value. The stock last closed at US$482.45, with a 7 day return of a 3.6% decline, a 30 day return of an 18.8% decline and a year to date return of an 18.8% decline, while the 1 year return sits at 49.4%, the 3 year return at 75.4% and the 5 year return at 285.3%. Recent attention on Madrigal Pharmaceuticals has centered on...

Moog Inc. reported strong first-quarter 2026 results on January 30, 2026, with sales rising to US$1,100.35 million and net income increasing to US$78.85 million, alongside higher earnings per share, a raised full-year sales outlook to US$4.3 billion, and a quarterly dividend lifted to US$0.30 per share. These moves, combined with the completion of a multi-year share repurchase program and ongoing confidence in aerospace and defense demand, signal management’s willingness to return cash to...

Cogent Biosciences (COGT) recently reported two closely linked FDA milestones for its lead cancer therapy, and those regulatory updates are now central to how many investors are thinking about the stock. See our latest analysis for Cogent Biosciences. The FDA’s Breakthrough Therapy Designation and Real-Time Oncology Review decision arrived after a period of very strong market interest, with the share price at $37.28 and a 90 day share price return of 158.53%. The 1 year total shareholder...

Enphase Energy (NasdaqGM:ENPH) is progressing its DC based IQ Bidirectional EV Charging Platform, with global pilot demonstrations and validation in the US and key European markets. The platform is being developed to support EV charging, home backup power and potential future grid services. The company is targeting volume production of the IQ Bidirectional EV Charging Platform beginning in late 2026. For you as an investor, this move extends Enphase Energy beyond its core residential solar...

If you are wondering whether Incyte's current share price lines up with its underlying worth, you are not alone. This article is designed to help you connect the dots between price and value. Incyte's share price recently closed at US$100.92, with returns of a 2.5% decline over 7 days, a 0.5% decline over 30 days, a 0.5% decline year to date, and a 36.2% gain over the past year, which hints at shifting expectations about the stock. Recent headlines around Incyte have focused on the company's...

Garmin (NYSE:GRMN) has introduced the Varia RearVue 820 radar tail light for cyclists. The product adds vehicle tracking, dynamic threat level alerts, and customizable lighting modes focused on rider safety. The launch expands Garmin's cycling safety technology lineup within its fitness and outdoor segment. For investors watching Garmin, the Varia RearVue 820 sits squarely in the company’s core fitness and outdoor business, where connected devices and safety features are an important part...

Byline Bancorp, Inc. reported past fourth-quarter 2025 results with net interest income of US$101.26 million and net income of US$34.52 million, alongside a 20% increase in its quarterly dividend to US$0.12 per share. The company also completed a share repurchase program and reduced net loan and lease charge-offs, highlighting capital return to shareholders while maintaining asset quality. Next, we'll examine how the earnings beat and dividend increase affect Byline Bancorp's investment...

Key Insights Given the large stake in the stock by institutions, Ambarella's stock price might be vulnerable to their...

New Oriental Education & Technology Group recently reported past second-quarter fiscal 2026 results showing higher sales and net income, issued revenue guidance projecting further year-over-year growth for the third quarter and full year, and completed a US$86.3 million repurchase of 1,600,000 shares representing 1.01% of its share base. The combination of improving profitability, management’s outlook for continued revenue expansion, and capital returned through completed buybacks highlights...

Why Arcellx Stock Is Back in Focus After New CAR T Data Arcellx (ACLX) is back on investors’ radar after late breaking data on its D Domain binder in anitocabtagene autoleucel was accepted for presentation at the 2026 Tandem Meetings. The abstract centers on preclinical comparisons of different BCMA targeted CAR T constructs, highlighting how binder design may affect specificity, safety signals, and cytokine release in multiple myeloma treatment. For investors, this development relates less...

If you are wondering whether Champion Homes is starting to look like value after a weak share price patch, this article will walk through what the current price might be implying about the business. The stock last closed at US$76.03, with returns of an 11.8% decline over 7 days, a 10.5% decline over 30 days, a 10.5% decline year to date, but a 10.5% gain over 3 years and an 81.1% gain over 5 years. This mix of short term weakness and longer term gains can leave investors questioning whether...

UnitedHealth Group (NYSE:UNH) is under Department of Justice investigation over its Medicare billing practices. Regulators are scrutinizing how the company handles Medicare Advantage payments and related coding activity. Proposed Medicare Advantage rates for 2027 include a near-zero increase, pressuring economics across the program. New Department of Labor rules call for extensive transparency from Pharmacy Benefit Managers that work with employers. For a company as large and diversified as...

Scholar Rock Holding's Chief Scientific Officer has executed multiple insider share sales under a pre-arranged 10b5-1 trading plan. The transactions come as the company readies apitegromab, its muscle-targeted treatment, for potential launch in the U.S. and Europe pending regulatory approvals. The timing links leadership share activity with a period of important commercialization preparations for the company. Scholar Rock Holding (NasdaqGS:SRRK) is drawing fresh attention as insider trading...

China Yuchai International recently reported that its earnings grew 29% over the past year, outpacing the broader machinery industry while advancing investments in new energy solutions and OEM partnerships. An interesting aspect of this update is the company’s balance sheet strength, with cash exceeding total debt, which may support ongoing technology investments. Next, we’ll examine how this combination of earnings growth and new energy investment shapes China Yuchai International’s broader...

Why Laureate Education is on investors’ radar today Laureate Education (LAUR) has drawn fresh attention after recent trading data highlighted its share performance over the past month and past 3 months, prompting investors to reassess the higher education provider’s current valuation. See our latest analysis for Laureate Education. The recent 90 day share price return of 12.17%, alongside a 1 year total shareholder return of 78.19% and very large 5 year total shareholder return, suggests...